A Retrospective Cohort Study of Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents With Lymphomas, Prognostic Tool Development, and Internal Prospective Validation.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Venous thromboembolism (VTE) is a significant complication in pediatric lymphoma patients, but no validated risk stratification tool exists. In this single-center cohort study, patients aged 18 years or younger with lymphoma were included. A retrospective cohort (N=262) was analyzed for risk factors for symptomatic VTE (sVTE) and prognostic tool development, while a prospective cohort (N=128) was used for validation. sVTE occurred in 8% of the retrospective cohort. Independent risk factors included: mediastinal tumor volume ≥250 mL (OR=4.42, 95% CI: 1.62-12.7), patient transfer to an intensive care unit due to a life-threatening condition within 30 days of admission (ICU+) (OR=4.27, 95% CI: 1.25-13.9), age 12 years or older (OR=7.43, 95% CI: 2.21-34.6), non-O blood type (OR=5.13, 95% CI: 1.5-24.5). A scoring system assigned points as follows: age 12 years or older (1 point), mediastinal mass ≥250 mL (2 points), ICU+ (2 points), and non-O blood group (1 point). A score ≥2 identified high-risk patients (AUC 0.75, sensitivity 0.75, specificity 0.64). The 1-year cumulative incidence of sVTE was 3.9% (95% CI: 0%-8.2%) in non-high-risk versus 18.3% (95% CI: 7.5%-29.2%) in high-risk groups ( P =0.008). This validated prognostic tool effectively stratifies thrombosis risk and may guide prophylactic strategies in pediatric lymphoma.